Headlines
-
AD drug knocked back
Tuesday | Mar 4 2025The Therapeutic Goods Administration (TGA) has confirmed its initial decision from Oct 2024 not to register lecanemab in Australia for use as an amyloid-lowering therapy for the treatment of mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's dementia (early Alzheimer's disease).
-
Systems focus for WOD
Tuesday | Mar 4 2025WORLD Obesity Day (WOD) takes place today, with this year's theme shining a spotlight on the systems that shape our health: 'Changing systems.
-
Yindyamarra: AdPha’s vision for 2030
Tuesday | Mar 4 2025ADVANCED Pharmacy Australia (AdPha) has released its six-year strategic plan, with the patient at the heart of everything they do.
-
AD drug knocked back
Tuesday | Mar 4 2025The Therapeutic Goods Administration (TGA) has confirmed its initial decision from Oct 2024 not to register lecanemab in Australia for use as an amyloid-lowering therapy for the treatment of mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's dementia (early Alzheimer's disease).
-
Systems focus for WOD
Tuesday | Mar 4 2025WORLD Obesity Day (WOD) takes place today, with this year's theme shining a spotlight on the systems that shape our health: 'Changing systems.
-
Yindyamarra: AdPha’s vision for 2030
Tuesday | Mar 4 2025ADVANCED Pharmacy Australia (AdPha) has released its six-year strategic plan, with the patient at the heart of everything they do.
-
AD drug knocked back
Tuesday | Mar 4 2025The Therapeutic Goods Administration (TGA) has confirmed its initial decision from Oct 2024 not to register lecanemab in Australia for use as an amyloid-lowering therapy for the treatment of mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's dementia (early Alzheimer's disease).
-
Systems focus for WOD
Tuesday | Mar 4 2025WORLD Obesity Day (WOD) takes place today, with this year's theme shining a spotlight on the systems that shape our health: 'Changing systems.
-
Yindyamarra: AdPha’s vision for 2030
Tuesday | Mar 4 2025ADVANCED Pharmacy Australia (AdPha) has released its six-year strategic plan, with the patient at the heart of everything they do.
-
AD drug knocked back
Tuesday | Mar 4 2025The Therapeutic Goods Administration (TGA) has confirmed its initial decision from Oct 2024 not to register lecanemab in Australia for use as an amyloid-lowering therapy for the treatment of mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's dementia (early Alzheimer's disease).
